Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
about
Hepatitis B and human immunodeficiency virus co-infectionApproved Antiviral Drugs over the Past 50 YearsPCR mediated recombination impacts the analysis of hepatitis B Virus covalently closed circular DNA.HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
P2860
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Role of a 48-week pegylated in ...... ding tenofovir: EMVIPEG study.
@en
Role of a 48-week pegylated in ...... ding tenofovir: EMVIPEG study.
@nl
type
label
Role of a 48-week pegylated in ...... ding tenofovir: EMVIPEG study.
@en
Role of a 48-week pegylated in ...... ding tenofovir: EMVIPEG study.
@nl
prefLabel
Role of a 48-week pegylated in ...... ding tenofovir: EMVIPEG study.
@en
Role of a 48-week pegylated in ...... ding tenofovir: EMVIPEG study.
@nl
P2093
P50
P1476
Role of a 48-week pegylated in ...... ding tenofovir: EMVIPEG study.
@en
P2093
Cécile Bouix
Fabien Zoulim
Fanny Lebossé
Lionel Piroth
Marianne Maynard-Muet
Patrick Miailhes
Philippe Sogni
Yoann Barthe
P304
P356
10.1016/J.JHEP.2014.05.030
P577
2014-06-02T00:00:00Z